



NDA 19-717/S-058

Eli Lilly and Company
Attention: Jeffrey L. Winn, D.D.S., R.Ph.
Senior Regulatory Research Scientist
U.S. Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Winn:

Please refer to your supplemental new drug application dated October 22, 2003, received October 23, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Humulin 70/30 (70% human insulin isophane suspension and 30% human insulin injection, [rDNA origin]).

We acknowledge receipt of your submissions dated February 19 and April 8, 2004.

This “Changes Being Effected” supplemental new drug application provides for labeling changes to the INFORMATION FOR THE PATIENT, Disposable Insulin Delivery Device (Humulin 70/30 Pen) User Manual, and carton label for Humulin 70/30 Pen.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the patient package insert, Humulin 70/30 Pen User Manual, and carton label for Humulin 70/30 Pen).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 19-717/S-058." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures: 1. INFORMATION FOR THE PATIENT (5.01 PA 9145 FSAMP)
 2. Humulin 70/30 Pen User Manual (5.01 PA 9115 FSAMP)
 3. Carton label for Humulin 70/30 Pen (SH 8733 FSAMS)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff

4/22/04 05:25:30 PM